CAJ | 학술논문

目的：探讨血清hMAM对乳腺癌患者新辅助化疗疗效的评估价值。方法选择45例女性乳腺癌患者和20例健康体检人群作为研究对象。对比2组患者血清hMAM表达情况，分析乳腺癌患者hMAM表达与临床病理情况的相关性。结果乳腺癌患者hMAM mRNA阳性表达占62．2％，显著高于对照组的0，P＜0．05。化疗1周、2周后 PR组的hMAM表达指数显著低于SD＋PD组，结果对比有统计学差异，P＜0．05。 hMAM阳性表达与TNN分期及ER的阳性表达密切相关。结论血清hMAM能作为诊断乳腺癌新辅助化疗患者预后的相关指标。
목적：탐토혈청hMAM대유선암환자신보조화료료효적평고개치。방법선택45례녀성유선암환자화20례건강체검인군작위연구대상。대비2조환자혈청hMAM표체정황，분석유선암환자hMAM표체여림상병리정황적상관성。결과유선암환자hMAM mRNA양성표체점62．2％，현저고우대조조적0，P＜0．05。화료1주、2주후 PR조적hMAM표체지수현저저우SD＋PD조，결과대비유통계학차이，P＜0．05。 hMAM양성표체여TNN분기급ER적양성표체밀절상관。결론혈청hMAM능작위진단유선암신보조화료환자예후적상관지표。
Objective To investigate the evaluation value of serum hMAM on the efficacy of neoadjuvant chemotherapy for breast cancer .Methods 45 breast cancer patients and 20 healthy patients were selected .hMAM expression of the 2 groups were compared ,and the relationship between hMAM expression of breast cancer patients and clinicopathological features were ana -lyzed.Results hMAM mRNA positive expression of the breast cancer patients was 62.2%,which was significantly higher than that of the control group (0),P<0.05.hMAM expression in PR(partial response)patients was significantly lower than those of the SD+PD ( stable disease;progressive disease ) patients 1 week and 2 weeks after chemotherapy ,there had statistical difference , P<0.05.hMAM positive expression was closely related to TNN staging and ER positive expression .Conclusion Serum hMAM can be used as relevant prognostic factors of neoadjuvant chemotherapy for breast cancer .